Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.59 |
| ▸ | CA2 | P00918 | 18/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 4/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA6 | P23280 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA3 | P07451 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329732 | 0.85 | CA1 (0.63) | CA1CA2MMP2CA7CA13 | |
| SCHEMBL940346 | 0.85 | CA1 (0.59) | CA1CA2MMP2CA7CA13 | |
| SCHEMBL31018987 | 0.85 | CA1 (0.59) | CA1CA2MMP2CA7CA13 | |
| SCHEMBL31670541 | 0.85 | CA1 (0.63) | CA1CA2MMP2CA7CA13 | |
| SCHEMBL1805995 | 0.85 | PARP1 (0.48) | CA1CA2MMP2CA7CA13 | |
| SCHEMBL1383113 | 0.85 | CA2 (0.56) | CA1CA2CA7CA13CA12 | |
| Hydrochloric Acid SCHEMBL7951765 | 0.84 | CA1 (0.61) | CA1CA2MMP2CA7CA13 | |
| SCHEMBL11091668 | 0.84 | CA1 (0.57) | CA1CA2MMP2CA7CA13 | |
| SCHEMBL1807551 | 0.84 | CA1 (0.57) | CA1CA2MMP2CA7CA13 | |
| SCHEMBL27878675 | 0.84 | CA1 (0.61) | CA1CA2MMP2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411006-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | GUPTA AJAY (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20180243265-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | CHARAK LLC (US) | 2018-08-30 | — | — | US | disclosed |
| US-20150258062-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | GUPTA AJAY (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-8404036-B2 | Water-soluble near-infrared absorbing coloring matters and aqueous inks containing same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2411006-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | Gupta, Ajay (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010111599-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | GUPTA AJAY (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249081-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | GUPTA AJAY | 2010-09-30 | — | — | US | disclosed |
| US-6818765-B1 | PREVENTION AND/OR TREATMENT OF ILLNESSES INVOLVING THROMBOXANE A2 AT DIFFERENT LEVELS | UNIVERSITE DE LIEGE (BE) | 2004-11-16 | — | — | US | disclosed |
| EP-1140810-B1 | BENZENIC SULPHONAMIDE DERIVATIVES AND THEIR USES | UNIV LIEGE (BE) | 2004-03-17 | — | — | EP | disclosed |
| US-4283407-A | ANTIHYPERTENSIVE AGENTS | SCIENCE UNION ET CIE (FR) | 1981-08-11 | — | — | US | disclosed |
| US-4156732-A | Certain pharmaceutical sulfamoylbenzoyl benzofurans, benzothiophenes, and indoles | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258062-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | REN, PYGL, PTGER3 | CA1 2839/4885CA2 819/4885MMP2 914/4885 |
| US-20180243265-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | REN, PYGL, PTGER3 | CA1 2839/4885CA2 819/4885MMP2 914/4885 |
| US-20100249081-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE | REN, PYGL, PTGER3 | CA1 2839/4885CA2 819/4885MMP2 914/4885 |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | IK, RB1, COL1A1 | CA1 798/4885CA2 1279/4885MMP2 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.